FDA clears Edwards' tricuspid valve repair device; Bayer's blood thinner asundexian approved in China
read at raps ↗ApprovalNeutral
The U.S. Food and Drug Administration has granted approval for Edwards Lifesciences' new tricuspid valve repair system, expanding treatment options for patients with tricuspid regurgitation.
In China, Bayer received regulatory clearance for its oral anticoagulant asundexian, marking the drug's first market entry outside of Europe.
Both approvals highlight ongoing innovation in cardiovascular therapies and could broaden market opportunities for the companies involved.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: FDA approves Edwards’ tricuspid valve repair device; Bayer wins Chinese approval for blood thinner asundexian”
read at raps ↗
comments(0)
5-min edit window · permanent after that